ReferenceID 5504
Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma
Am J Cancer Res
Human hepatocellular carcinoma (HCC) is the most frequent cancer worldwide with a poor prognosis. Tumor-specific pyruvate kinase M2 (PKM2) is essential for cancer metabolism and tumorigenesis. Shikonin, a specific inhibi
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 5504
- Evidence Id
- 22094
- Core Evidence Id
- 22094
- Source Reference Id
- 4252
- Herb2 Reference Id
- HBREF005049
- Subject Paper Key
- HBIN030442_34354861
- Pubmed Id
- 34354861
- Doi
- Paper Title
- Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma
- Paper Abstract
- Human hepatocellular carcinoma (HCC) is the most frequent cancer worldwide with a poor prognosis. Tumor-specific pyruvate kinase M2 (PKM2) is essential for cancer metabolism and tumorigenesis. Shikonin, a specific inhibitor of PKM2, but not PKM1, exhibits significant anticancer effect in HCC, and was deemed as a promising drug for cancer therapy. However, shikonin-mediated bypass signaling in HCC remained unclear. Here, we performed forward/reverse stable isotope labeling with amino acids in cell culture (SILAC)-based proteomics to identify the early molecular events controlled by shikonin. We demonstrated for the first time that shikonin could induce the nuclear translocation of PKM2 for recruiting Nrf2, and transcriptionally activated Nrf2 downstream target gene BAG3, therefore increasing protective effect to sustain cell survival. Knockdown of BAG3 by si-RNA significantly potentiated the anticancer effect of shikonin. These findings provided the first evidence of a new noncanonical function of inhibited PKM2 could act as a transcriptional coactivator of Nrf2 in cancer survival, highlight that shikonin in combined with BAG3 inhibitor could be a promising therapeutic strategy for HCC therapy.
- Journal
- Am J Cancer Res
- Publish Year
- 2021
- Experiment Subject
- human
- Experiment Type
- Cell Experiment
- Phenotype Related
- Cancer; Hepatocellular Carcinoma
- Paper Title Cn
- Paper Title En
- Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma
- Bilingual Status
- semi_complete